Amgen in Thousand Oaks. (courtesy photo) Thousand Oaks-based Amgen shared strong third-quarter results on Oct. 30, beating expectations, but all eyes appear to be on the big biotech's future, which includes trial data from its potentially blockbuster obesity medicine that it said will come out before the end of the year. Amgen, one of the largest…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
